jRCT2031210530已完成不适用
ONO-7914-01:A Phase I, open-label, uncontrolled, dose escalation study to evaluate the tolerability and safety of ONO-7914 alone and in combination with ONO-4538 in patients with advanced or metastatic solid tumors
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 204
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized Controlled Trial
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 75age old under（—）
- 性别
- All
入选标准
- •1.Patients with advanced or metastatic solid tumor
- •2.Patients with ECOG performance status of 0 or 1
- •3.Patients with a life expectancy of at least 3 months
排除标准
- •1.Patients with severe complication
- •2.Patients judged to be incapable of providing consent for reasons such as concurrent dementia
结局指标
主要结局
-
Safety and tolerability
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
ONO-7913-04: ONO-7913 Phase 1 StudyJPRN-jRCT2051210038Hirashima Yoshinori60
进行中（未招募）
不适用
ONO-7475-04:A Phase1 study of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and ONO-7475 in combination with GnP in patients with pancreatic cancerjRCT2031230429Ono Pharmaceutical Co.,LTD87
招募中
1 期
ONO-7914-01:Phase I study of ONO-7914 alone and in combination with ONO-4538 in patients with solid tumorsJPRN-jRCT2031210530Hirashima Yoshinori204
招募中
不适用
ONO-7428-01: A phase I study of ONO-7428 in participants with unresectable advanced or recurrent solid tumorsjRCT2031240647Ono Pharmaceutical Co.,LTD60
进行中（未招募）
1 期
ONO-4578-03:ONO-4578 Phase 1 StudyJPRN-jRCT2051200096Hirashima Yoshinori30